Mineralys Therapeutics Inc. (MLYS)
MLYS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | MLYS on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2023 |
| SEC CIK | 0001933414 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DELAWARE |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-04 |
| Cash and burn | $101.3M cash; operating cash flow -$38.3M a quarter. | Report 2026-09-30 |
| Shares outstanding | 88,557,097 (2026-10-29); 79,139,956 a year earlier; 41,105,118 three years earlier. | Cover page 2026-10-29 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-06-03 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Denver, Colorado, United States | PCAOB Form AP 2026-03-25 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $8.8M, sold $87.6M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$57.3M | -$43.1M | $101.3M | $100K | Needs four quarters | 10-Q 2026-11-04 |
| Q2 2026 2026-06-30 | Not filed | -$241.1M | -$32.6M | $138.3M | $100K | Needs four quarters | 10-Q 2026-11-04 |
| Q1 2026 2026-03-31 | Not filed | -$39.3M | -$39.5M | $112.8M | No debt tags | Needs four quarters | 10-Q 2026-11-04 |
| Q4 2025 2025-12-31 | Not filed | -$32.2M | -$37.9M | $172.9M | No debt tags | Needs four quarters | 10-K 2026-03-12 |
| Q3 2025 2025-09-30 | Not filed | -$36.9M | -$28.9M | $217.6M | No debt tags | Needs four quarters | 10-Q 2026-11-04 |
| Q2 2025 2025-06-30 | Not filed | -$43.3M | -$30.2M | $101.8M | No debt tags | Needs four quarters | 10-Q 2026-11-04 |
| Q1 2025 2025-03-31 | Not filed | -$42.2M | -$45.5M | $165.0M | No debt tags | Needs four quarters | 10-Q 2026-11-04 |
| Q4 2024 2024-12-31 | Not filed | -$48.9M | -$66.8M | $114.1M | No debt tags | Needs four quarters | 10-K 2026-03-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-06-03 |
| Latest annual report | 10-K | 2026-03-12 |
| Latest quarterly / interim | 10-Q | 2026-11-04 |
| Latest current report | 8-K | 2026-11-04 |
| Latest proxy | DEFA14A | 2026-04-08 |
Source: SEC EDGAR submissions feed, 408 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | 0.0% |
| 1 month | -27.0% |
| 3 months | -41.2% |
| Year to date | -57.8% |
| 1 year | -65.4% |
| From 52-week high | -65.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| GHRS | GH Research PLC | $18.75 | -1.83% | $1.3B |
| MNKD | MannKind Corporation | $3.96 | -4.24% | $1.3B |
| INVA | Innoviva Inc. | $18.49 | -2.84% | $1.3B |
| OCUL | Ocular Therapeutix Inc. | $6.01 | -3.22% | $1.3B |
| AVLN | Avalyn Pharma Inc. | $29.76 | -1.72% | $1.3B |
| NKTR | Nektar Therapeutics | $36.44 | -2.23% | $1.2B |
| GPCR | Structure Therapeutics Inc. | $18.57 | -7.15% | $1.3B |
| AMPH | Amphastar Pharmaceuticals Inc. | $29.17 | -0.68% | $1.2B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier